Trials / Terminated
TerminatedNCT00152594
Voriconazole or Placebo in the Prophylaxis of Lung Infiltrates in Patients Undergoing Induction Chemotherapy for Acute Myelogenous Leukemia
Phase III Study of Safety, Tolerance, Efficacy, Pharmacokinetics, and Costs of Therapy With Voriconazole or Placebo in the Prophylaxis of Lung Infiltrates in Patients Undergoing Induction Chemotherapy for Acute Myelogenous Leukemia
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 150 (planned)
- Sponsor
- University of Cologne · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to determine whether voriconazole is as effective as antifungal prophylaxis in patients undergoing chemotherapy for acute myelogenous leukemia (AML). Hypothesis: Voriconazole is superior to placebo in the prophylaxis of lung infiltrates until day 21 after the start of induction chemotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | voriconazole |
Timeline
- Start date
- 2004-10-01
- Completion
- 2006-01-01
- First posted
- 2005-09-09
- Last updated
- 2006-11-14
Locations
3 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT00152594. Inclusion in this directory is not an endorsement.